🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

So, so thrilled that our small but mighty team at STAT has won its first National Magazine Award for General Excellence. The judges cited 3 of STAT's series from last year, incl. Health Care's Colossus, our investigation into UnitedHealth Group. shorturl.at/g0x3O

Median age of survival for cystic fibrosis patients was 4-5 in 1954. I’m 34 in 2025. Today, some median project survival analyses say CF patients born today can expect to live to be 70+ Feels like we’re healthier now than ever before.

Verve gene-editing therapy lowers cholesterol without serious side effects in early study statnews.com/2025/04/14/ver… via STAT Congratulations Verve.

📢 New VT Research! The IRA is driving a 68% aggregate drop in early-stage funding for small molecule drugs, with early-stage clinical trials also in decline. Our latest report shows how this puts future treatments for seniors at risk. Read more: buff.ly/pkV8vHB #IRA

Money come and go. Harvard did the right thing.

Way too many early phase biotechs like this...

Why has early-stage funding for small molecule drugs dropped 68%, from $2B to $640M? The IRA’s 9-year price-setting window shortens their return period, increasing risk and driving early-stage capital elsewhere. Read our latest findings: buff.ly/pkV8vHB We Work For Health

My worry is that they will change it to 9 years for both small molecules and biologicals. Thus, the penalty will be even worse.

Ligand subsidiary Pelthos Therapeutics to merge with Channel Therapeutics Corp. The transaction will raise $50 million in equity capital, and the combined company will focus on commercializing ZELSUVMI™ for molluscum. Ligand is entitled to a 13% royalty on worldwide sales. bit.ly/4cAe11r

The IRA sets Medicare’s maximum fair price at year 9 for small molecule drugs, 4 years sooner than for biologics. Since then, early-stage small molecule funding has dropped. Expect fewer new treatments for seniors by 2030. Read more: buff.ly/pkV8vHB We Work For Health

Claims that the IRA wouldn’t affect innovation overlooked how early-stage investors really make decisions. Our research shows the pipeline for senior-focused therapies is already narrowing. Read the full breakdown: buff.ly/Agz6GuJ We Work For Health #IRA #DrugPricing

Removal of the Pharma Advisory Committee rep is an issue. This is a nonvoting member not connected to the sponsor and an expert in the field. Plus PDUFA ensures such representation. Removal perpetrates the view of “evil Pharma”.

We’re proud to share new research in BMC Pulmonary Medicine (BMC) that captures the real-world experiences of people living with #idiopathicpulmonaryfibrosis. Conducted with #IPF experts & @PFForg, it highlights gaps in diagnosis, treatment options, and quality of

Just presented at #ATS2025: New preliminary 52-week open-label extension data from our Phase 2b ELEVATE #IPF trial reinforce deupirfenidone’s strong and durable efficacy — slowing lung function decline to the range expected in healthy older adults, with favorable tolerability.

Meet India’s Self-Made Biologics Brewmaster Billionaire on.forbes.com/6014NL2lG (Photo: Guerin Blask For Forbes)

Paolo Tarantino Honored to Receive the 2025 Yvonne 'Top Voice' Award Presented by OncoDaily Paolo Tarantino Luiza Pamela Beato G Curigliano MD PhD oncodaily.com/positive/yvonn… #Cancer #Oncology #OncoDaily #Health #ASCO25 #ASCO #Medicine CancerWorld

A molecular variant of an older, hard-to-tolerate antifibrotic agent showed promise for reducing decline in forced vital capacity (FVC) over 26 weeks among patients with idiopathic pulmonary fibrosis (IPF). ms.spr.ly/6016SiGCs

There are a LOT of problems with the FDA Commissioner's National Priority Vouchers. First that they're given out by the commissioner. But also: faster drug approvals are good, but these would be faster than any drug approvals ever. Big promises like this should be approached

In an ever-evolving healthcare landscape, understanding how policy shapes innovation becomes increasingly important. Without that understanding - barriers to drug development, such as uneven exclusivity periods, can halt the development of new treatments. We sat down for a

Most of the CRL stuff should already be in the review docs for those diligent enough to go through them